Janssen Cilag International

Address: Turnhoutseweg 30

Sponsor Overview

assignment

199

Specializations

Haematologic Malignancies and Blood Disorders

Multiple myeloma, relapsed or refractory myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic neoplasms, and AL amyloidosis are prominent areas of interest, alongside studies in mantle cell lymphoma and other B-cell malignancies.

Multiple myeloma and plasma cell disorders
B-cell non-Hodgkin lymphoma and CLL/SLL
Acute leukemia and myelodysplastic neoplasms

Research also extends to warm autoimmune hemolytic anemia and other haematology-focused conditions.

Oncology in Solid Tumours

The sponsor funds research in non-small cell lung cancer, prostate cancer, urothelial cancer, bladder cancer, colorectal cancer, head and neck squamous cell carcinoma, and other advanced solid tumors, including metastatic and recurrent disease settings.

Non-small cell lung cancer
Prostate cancer
Urothelial and bladder cancers

Additional activity includes studies in gastric cancer, advanced solid tumors, and biomarker-defined tumour populations.

Immune-Mediated and Inflammatory Diseases

Clinical research includes psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's disease, and idiopathic inflammatory myopathies, with both adult and paediatric populations represented.

Psoriasis and psoriatic arthritis
Inflammatory bowel disease
Systemic autoimmune and rheumatologic disease

Work also covers atopic dermatitis, asthma, and chronic inflammatory demyelinating polyneuropathy.

Neurology, Psychiatry, and Ophthalmology

Janssen Cilag International supports studies in Alzheimer’s disease, major depressive disorder, bipolar depression, myasthenia gravis, chronic inflammatory neuropathies, and stroke prevention, together with ophthalmic research in geographic atrophy and X-linked retinitis pigmentosa.

Alzheimer’s disease and cognitive decline
Depression and related mood disorders
Neuromuscular and retinal disorders

Further interest includes acute suicidal ideation and healthy volunteer studies supporting neurological and psychiatric development.

Cardiovascular, Maternal, Infectious, and Metabolic Conditions

The portfolio also includes atrial fibrillation, acute coronary syndrome, atherothrombotic and thromboembolic disorders, acute ischemic stroke, and metastatic castration-sensitive prostate cancer with cardiovascular-relevant treatment questions, as well as maternal-fetal conditions such as hemolytic disease of the fetus and newborn and fetal and neonatal alloimmune thrombocytopenia.

Atrial fibrillation and ischemic stroke
Maternal-fetal haematology
Hepatitis B and hepatitis D co-infection

Research activity also includes tuberculosis, renal impairment, and healthy adult participant studies relevant to drug disposition and clinical use.

Sponsored Trials

Trial Name	Country	Status
A Phase 1 Study of JNJ-95437446 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer, or Head and Neck Squamous Cell Carcinoma	Spain	Recruiting
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Bioavailability and Food Effect of Various Oral Formulations of a Novel Investigational Compound in Healthy Volunteers	The Netherlands	Not Recruiting
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-88545223 in Participants with Active Psoriatic Arthritis	Czechia Germany Hungary Poland Spain	Recruiting
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Belgium Finland France Germany Greece Italy Poland Portugal Spain	Recruiting
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)	Belgium Czechia Denmark Germany Hungary Italy Poland Portugal Spain Sweden The Netherlands	Not Recruiting
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease	Belgium Czechia France Germany Greece Hungary Italy Poland Portugal Romania Spain Sweden The Netherlands	Recruiting
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide	Austria Belgium Czechia Denmark France Germany Greece Hungary Italy Poland Spain Sweden The Netherlands	Not Recruiting
A Phase 3 Randomized Study of Lazertinib and Subcutaneous Amivantamab Versus Intravenous Amivantamab in EGFR-Mutated Advanced NSCLC Post-Osimertinib and Chemotherapy	France Germany Italy Poland Portugal Spain	Not Recruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer	Belgium France Germany Italy Poland Spain The Netherlands	Recruiting
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis	Belgium Czechia France Germany Greece Hungary Italy Poland Portugal Romania Spain Sweden The Netherlands	Recruiting